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Background:
 
 Type 2 diabetes is now recognized as a
major public health concern but its burden on society is
under-researched.
 
Methods:
 
 T
 
2
 
ARDIS was a postal survey of 1578 people
with type 2 diabetes across four UK centres, incorporat-
ing measures of resource use, treatment satisfaction and
health-related quality of life (HrQoL). The findings in-
cluded data on the EQ-5D that enabled the HrQoL bur-
den of the disease to be established by comparison with
equivalent data for the general population and the dia-
betic population as a whole from the 1996 Health Sur-
vey of England.
 
Results:
 
 The results indicate a significant deficit experi-
enced by people with type 2 diabetes vs. their age group
peers in the general population. The proportion of
T
 
2
 
ARDIS respondents reporting problems increases in
relation to the presence of complications, and microvas-
cular complications appear to have more impact than
macrovascular complications.
 
Conclusions:
 
 This confirms the need for treatment poli-
cies to focus on reducing the risk of such complications
and hence improve patients’ HrQoL.
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Introduction
 
Type 2 diabetes is associated with significant mor-
bidity and mortality and is now recognized as a
major public health concern [1]. Complications of
the condition include retinopathy, heart disease,
stroke and kidney damage. However, few studies
have attempted to identify the overall costs of dia-
betes to society [2] and type 2 diabetes has been
particularly under-researched in this respect.
The Type 2 Diabetes: Accounting for a Major
Resource Demand In Society in the UK (T
 
2
 
ARDIS)
survey was undertaken to investigate the direct,
indirect and intangible costs associated with the
condition in order to improve understanding of
the overall burden it imposes. The direct and indi-
rect cost findings are being reported elsewhere; the
overall cost to the NHS of people with type 2 dia-
betes is in the region of £2 billion per year, driven
predominantly by in-patient care [3].
This paper reports on the intangible costs of
type 2 diabetes expressed in terms of the impact
on HrQoL. In particular, for the first time it estab-
lishes the burden of disease by comparing T
 
2
 
ARDIS
findings with equivalent data from the UK general
population and the diabetic population as a whole
from the Health Survey of England (HSE 1996) [4].
The T
 
2
 
ARDIS findings also allow examination
of the impact of complications on HrQoL to sup-
plement that reported by the UKPDS Group [5].
While the UKPDS analysis found that therapeutic
policies known to reduce the risk of complications
had no effect on HrQoL, the current paper rein-
forces the need for further attention to be paid to
this issue in order to reduce the significant quality
of life burden of the condition.
 
Methods
 
A postal survey of 1578 people with type 2 diabetes
was undertaken in the period April to August 1999
across four UK centres with local diabetes registers:
Brighton, Hemel Hempstead, Newcastle and La-
narkshire. Each of these registers encompassed data
from at least 80% of local GP practices, and in-
cluded diabetic patients seen only in primary care
as well as those seen in secondary care.
Identification of patients with type 2 diabetes
was based on a confirmed type 2 diagnosis re-
corded on the register (Hemel Hempstead and La-
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narkshire) or diagnosis of unspecified type at age
30 or over (Brighton and Newcastle). Using this
definition, a random sample of 750 patients from
each centre was identified and a total of 3000
questionnaires distributed.
A battery of four instruments was included in the
T
 
2
 
ARDIS questionnaire for self-completion by the
patient and/or their informal carer: a 3-month retro-
spective review of resource use, the Diabetes Treat-
ment Satisfaction Questionnaire (DTSQ) [6], the
Caregiver Strain Index (CSI) [7] and the EQ-5D.
The EQ-5D is a two-part questionnaire devel-
oped by the EuroQol Group and designed as a ge-
neric measure of health-related quality of life [8].
EQ-5D defines health in terms of five dimensions:
mobility, self-care, usual activities, pain or dis-
comfort, and anxiety or depression. Within each
dimension there are three levels of response indi-
cating no problems, some problems or extreme
problems on that dimension. Taken together, this
descriptive system defines a total of 243 unique
health states. Responses to the first part of EQ-5D
can be presented separately for each dimension in
the form of a profile (EQ-5D
 
profile
 
) or converted
into a single weighted index score (EQ-5D
 
index
 
) us-
ing population preference scores [9]. The second
part of EQ-5D consists of a 20-cm visual analogue
scale with endpoints of 0 denoting the worst imag-
inable state and 100 denoting the best imaginable
state used to record the respondents perception of
their overall health status (EQ-5D
 
VAS
 
).
Approximately three weeks following distribu-
tion of questionnaires to the T
 
2
 
ARDIS sample, each
centre carried out a telephone follow-up to nonre-
spondents. Response bias checks were carried out
using data available on the center registers, namely
the proportion of males vs. females, the proportion
aged over 65, and the proportion receiving insulin.
The respondents did not differ significantly from
the nonrespondents on any of these variables.
Comparison was made with the EQ-5D
 
index
 
 data
reported in the Health Survey for England (HSE)
[3]; EQ-5D
 
VAS
 
 data was not reported in the HSE.
The HSE is an annual series of national surveys of
the population living in England. The 1996 survey
sample was based on 12,960 addresses selected
from the national Postcode Address File. Inter-
views were obtained from 20,328 persons in total,
of whom 16,443 were aged 16 and over. The data
obtained on chronic illnesses included diabetes, al-
though this was not broken down according to
type or complication status.
Diabetic complications in T
 
2
 
ARDIS were catego-
rized as follows: no complications, 
 
n
 
 
 

 
 864 (57%);
microvascular complications (i.e., eye problems as-
sociated with diabetes, kidney damage, amputa-
tion, foot or leg ulcers), 
 
n
 
 
 

 
 364 (24%); macrovas-
cular complications (i.e., stroke and/or heart attack),
 
n
 
 
 

 
 178 (12%); and both macro-and microvascular
complications, 
 
n
 
 
 

 
 104 (7%).
The data on complications were taken from the
survey questionnaires, i.e., self-reported, based on
prompts. Terminology used to capture this informa-
tion was designed to assist ease of completion and
to avoid unnecessary complexity. Responses are
therefore more likely to reflect patients’ own percep-
tions of their overall complication status rather than
objective clinical diagnoses. Nevertheless, the au-
thors consider that the prompts were sufficiently
clear that respondents would know if they suffered
from any of the respective complications.
 
Results
 
Of the 3000 T
 
2
 
ARDIS questionnaires distributed
across the four study centres, 1578 were returned,
yielding a 53% response rate (Table 1).
The mean age ranged between 63 and 69 across
all four centres. However, in Lanarkshire and
Newcastle a smaller proportion of respondents
were aged over 65. There were more males in
Hemel Hempstead and Lanarkshire, and propor-
tionately more smokers in Lanarkshire. Differ-
ences in treatment regimen are illustrated by the
higher proportion of respondents in Newcastle re-
ceiving insulin, either alone or in combination
with oral antidiabetic tablets.
For the purposes of examining HrQoL, these
data have been aggregated. A total of 68 (4%) re-
spondents did not provide data on all five dimen-
sions of the EQ-5D
 
profile
 
 and these were excluded
from the analysis. There was no evidence of bias
arising from these exclusions.
 
Table 1
 
T
 
2
 
ARDIS sample characteristics by centre
 
BT HH NC LS All
Type 2 diabetics on register 3602 1600 2501 7523 15226
T
 
2
 
ARDIS sample 750 750 750 750 3000
T
 
2
 
ARDIS respondents 414
(55%)
373
(50%)
420
(56%)
371
(50%)
1578
(53%)
Mean age (yrs) and (SD) 68
(10.7)
69
(11.1)
66
(12.0)
63
(11.2)
67
(11.5)
Age 
 

 
65 (%) 66 64 54 48 58
Male (%) 53 59 52 59 56
Smokers (%) 15 13 16 20 16
Insulin (%) 19 19 28 15 20
Mean years since 
diagnosis and (SD)
9
(7.2)
9
(7.1)
8
(9.5)
8
(6.0)
8
(7.6)
 
BT 
 

 
 Brighton; HH 
 

 
 Hemel Hempstead; NC 
 

 
 Newcastle; LS 
 

 
 Lanarkshire.
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Comparison with HSE data
 
The percentage of patients reporting problems (ei-
ther some problems or extreme problems) across
the five dimensions of the EQ-5D
 
index
 
,
 
 is shown in
Table 2. Comparison was made with both the
overall population data from the HSE and with
the diabetic subpopulation from the HSE.
The most commonly reported problem areas
are on the mobility and pain/discomfort dimen-
sions. Overall, there is a strong similarity between
the EQ-5D
 
profile
 
 for the T
 
2
 
ARDIS study population
and that for the HSE diabetic population.
A chi-square test indicated that both the
T
 
2
 
ARDIS and the HSE diabetic population dem-
onstrate significantly more problems (some plus
extreme) than the general population across each
of the five dimensions (
 
P
 
 
 

 
 .01). However, a
lower proportion of the T
 
2
 
ARDIS population re-
port problems on the pain/discomfort dimension,
as compared with the HSE diabetic population,
and a higher proportion report problems on the
anxiety/depression dimension.
Figure 1 plots the T
 
2
 
ARDIS findings against the
age-standardized EQ-5D
 
index
 
 for the HSE diabetic
respondents and the HSE general population.
Across all four age groups the 95% confidence
intervals for the T
 
2
 
ARDIS patients and the HSE
diabetic population overlap, providing evidence of
the overall similarity of the two sets of EQ-5D
data. 
 
P
 
-values ranging from 0.10 for the 45–64-
year-old age group to 0.96 for the 
 

 
45-year-old
age group indicate that the T
 
2
 
ARDIS findings for
type 2 diabetes are not significantly different to
those for the overall diabetic population of England
(which includes both type 1 and type 2 diabetes).
Figure 1 also illustrates a significant HrQoL
deficit for type 2 diabetes when compared with
EQ-5D
 
index
 
 data for the general population. This
deficit is most marked in the youngest age group
where T
 
2
 
ARDIS respondents record a differential
of 0.15 on the EQ-5D
 
index
 
. This represents a loss of
0.15 of a year of full health (i.e., without prob-
lems on any EQ-5D dimension) or 1.5 years of full
health over a 10-year period.
However, the mean EQ-5D
 
index
 
 values tend to
converge with increased age. The mean value for
the T
 
2
 
ARDIS population appears reasonably sta-
ble across the age groups, whereas in the general
population this value decreases markedly. 
 
P
 
-val-
ues indicate a significant difference between the
general population and the T
 
2
 
ARDIS population
(
 
P
 
 
 

 
 .01) for the 
 

 
45, 45–64 and 65–74 year old
age groups. Only the 75
 

 
-year-olds show no sig-
nificant difference (
 
P
 
 
 

 
 .0489).
 
Analysis by Complication Status
 
Table 3 shows the EQ-5D
 
profile
 
 
 
associated with
each of the complications categories. Patients with
no complications record lower rates of problems
on all EQ-5D dimensions than patients with com-
plications. Those patients suffering from both mi-
crovascular and macrovascular complications re-
port problems far more frequently than those with
only one category of complications. There is also a
tendency for those with microvascular complica-
tions to report problems more often than those
with macrovascular complications. This is most
pronounced on the usual activities dimension.
In order to standardize for other factors known
to influence EQ-5D responses, a subset of patients
across all four complications categories was matched
in terms of 10-year age group, gender and smoking
status (EQ-5D
 
index
 
,
 
 
 
n
 
 
 

 
 89; EQ-5D
 
VAS
 
, 
 
n
 
 
 

 
 94). The
 
Table 2
 
EQ-5D
 
profile
 
 for T
 
2
 
ARDIS and HSE samples 
(percentage of respondents in each sample reporting problems)
 
EQ-5D Level
of problems
T
 
2
 
ARDIS 
All Patients
(
 
n
 
 
 

 
 1510)
HSE 1996
Diabetics
(
 
n
 
 
 

 
 360)
General population
(
 
n
 
 
 

 
 17076)
Mobility
Some 47.2% 45.7% 17.1%
Extreme 0.4% 0.3% 0.1%
Self-care
Some 14.8% 17.1% 4.6%
Extreme 1.2% 1.8% 0.4%
Usual activities
Some 35.0% 36.4% 15.9%
Extreme 6.6% 9.1% 2.4%
Pain/discomfort
Some 40.9% 48.7% 32.8%
Extreme 7.7% 10.9% 3.3%
Anxiety/depression
Some 34.7% 29.9% 20.9%
Extreme 5.3% 4.4% 1.8%
Figure 1 EQ-5Dindex in diabetics and the general population,
by age group (mean scores and 95% confidence intervals).
  T2ARDIS Population (n  1510).   HSE 1996 Diabetics
(n  360).   HSE 1996 General Population (n  17076).
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difference in the mean score of each complication cat-
egory vs. no complications was significant (
 
P
 
 
 
 .01).
A chi-square test indicated that the presence of
complications was also associated with a higher
number of reported problems across four of the
five individual dimensions which comprise the
EQ-5Dindex. The exception was self-care; this may
be linked to the fact that more respondents with
complications reported that they have a regular in-
formal carer, 141 (37%) in the microvascular cat-
egory, 79 (43%) in the macrovascular category
and 60 (56%) in the both micro- and macrovascu-
lar category, as compared with 217 (24%) for pa-
tients with no complications.
Reported problems with anxiety/depression were
only associated with the combination of both mi-
cro- and macrovascular complications. This is rel-
evant to the high level of problems reported on
this dimension compared to the HSE diabetic pop-
ulation shown in Table 2, and may be particularly
pronounced in the type 2 diabetic population.
Respondents on insulin reported problems more
often (P  .01) on the mobility, usual activities and
pain/discomfort dimensions than those on other treat-
ment regimens.
Discussion
Although drawn from only four selected UK cen-
tres, the T2ARDIS survey responses may be consid-
ered broadly representative of the national picture
on the HrQoL burden of type 2 diabetes. Compari-
son with the HSE data indicates a strong similarity
with the overall diabetic population (including both
type 1 and type 2) and confirms the significant defi-
cit experienced by people with type 2 diabetes vs.
their age group peers in the general population.
The proportion of T2ARDIS respondents re-
porting problems on the EQ-5Dindex increases in re-
lation to the presence of self-reported complica-
tions. Microvascular complications appear to have
more impact than macrovascular complications,
and over half the respondents with the former re-
port problems on mobility, usual activities and pain/
discomfort. However, this comparison is amongst
survivors and consequently does not take into ac-
count the impact of macrovascular complications
on mortality. Within this survivor population, the
cumulative nature of complications in type 2 diabe-
tes may also lie behind the high level of reported
problems on anxiety/depression.
T2ARDIS has shown that type 2 diabetes is a seri-
ous condition in terms of reduced HrQoL, and is
costly both to the NHS [3] and to the individual pa-
tient. The Audit Commission [2] has reinforced the
scale of the challenge faced in the provision of diabe-
tes services in the UK in order to alleviate this bur-
den. The UKPDS has confirmed that aggressive man-
agement of the risk factors of diabetes through blood
glucose control prevents complications [10] and we
now have evidence that complications are directly
linked to intangible costs in the form of HrQoL.
There is consequently a need for increased emphasis
on therapeutic policies that are specifically targeted
at reducing the risk of complications. This would
have substantial benefits in terms of improved qual-
ity of life for people with type 2 diabetes.
Source of funding: The T2ARDIS survey was funded en-
tirely by an educational grant from SmithKline Beecham
Pharmaceuticals.
The authors would like to acknowledge the generous co-
operation of the medical, nursing and administrative staff
Table 3 EQ-5Dprofile by diabetic complication category (percentage of respondents in each category reporting problems)
EQ-5D Level
of problems
No
complications
(n  864)
Microvascular
complications
(n  364)
Macrovascular
complications
(n  178)
Both micro & macrovascular
complications
(n  104)
Mobility
Some 34.0% 60.2% 56.7% 83.7%
Extreme 0.2% 0.3% 0.6% 1.9%
Self-care
Some 7.9% 20.9% 19.1% 36.5%
Extreme 0.5% 2.5% 0.6% 3.8%
Usual activities
Some 27.1% 46.2% 37.1% 55.8%
Extreme 2.9% 9.1% 10.1% 20.2%
Pain/discomfort
Some 35.0% 47.5% 43.8% 58.7%
Extreme 4.9% 11.8% 7.9% 15.4%
Anxiety/depression
Some 28.8% 39.6% 36.5% 55.8%
Extreme 2.9% 7.1% 5.1% 10.6%
Health-Related Quality of Life in Type 2 Diabetes S-51
and their patients at each of the four centres involved in
the T2ARDIS survey.
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